

Oxycontin (Oxycodone Extended Release)

POLICY NUMBER: RX.PA.090.E

REVISION DATE: 04/17

PAGE NUMBER: 2 of 3

- Must have a diagnosis of pain severe enough to require daily, around-the-clock, long term opioid treatment
- For adults age 18 years and older: Must submit chart documentation showing the member has tried both of the following medications for at least one month each with an inadequate response or significant side effects unless there is a documented contraindication to these medications:
 - Fentanyl patch
 - Morphine sulfate extended-release
- For pediatrics age 11 years and older:
 - Must be on opioids for five consecutive days with a minimum of 20mg per day of oxycodone or its equivalent for at least two days immediately preceding dosing with oxycodone ER
 - Must submit chart documentation showing the member has tried morphine sulfate ER for at least one month with an inadequate response or significant side effects/toxicities unless there is a contraindication to this medication
 - Must submit documentation of the anticipated duration of therapy

Reauthorization Criteria:

All prior authorization renewals are reviewed on an annual basis to determine the medical necessity for continuation of therapy. Authorization may be extended at 1 year intervals based upon chart documentation from the prescriber that the member's condition has improved based upon the prescriber's assessment while on therapy.

Limitations:

Length of Authorization (if above criteria met)	
Initial Authorization	Adults: Up to 1 year Pediatrics: anticipated duration of therapy or up to 1 year (whichever is shorter)
Reauthorization	Up to 1 year
Quantity Limits	
Oxycontin	60 tablets per month

If the established criteria are not met, the request is referred to a Medical Director for review.

REFERENCES

1. Oxycontin [package insert]. Stamford, CT: Purdue Pharma L.P.; August 2015.
2. WHO's Pain Ladder, World Health Organization; Accessed 6/17/08 at <http://www.who.int/cancer/palliative/painladder/en/>
3. Friedrichsdorf SJ and Kang TI. The management of pain in children with life-limiting illnesses. 1. Pediatric CLin N Am. 2007; 54: 645-672.
4. Brasher CB et al. Postoperative pain management in children and infants: an update. Pediatr Drugs. 2014; 16: 129-140.

RECORD RETENTION

Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure.



Oxycontin (Oxycodone Extended Release)
POLICY NUMBER: *RX.PA.090.E*
REVISION DATE: 04/17
PAGE NUMBER: 3 of 3

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
<i>Annual Review</i>	<i>02/16, 02/17, 02/18</i>
<i>Removal of Opana ER and Methadone as prerequisites</i>	<i>06/17</i>

